VVT Med Inc.
VVT Med Inc. develops, manufactures, and commercializes minimally invasive, non-thermal, and nontumescent solutions for the treatment of varicose veins. It offers V-BLOCK, a treatment kit for leg vein; VAR-01, a treatment kit for leg varicosities; VAR-02, a treatment kit for shallow varicosities; VAR-P " 06, a treatment kit for perforant veins failure; and Spider-01, a treatment kit for spider ve… Read more
VVT Med Inc. (VVTM) - Net Assets
Latest net assets as of September 2025: CA$-576.00K CAD
Based on the latest financial reports, VVT Med Inc. (VVTM) has net assets worth CA$-576.00K CAD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.93 Million) and total liabilities (CA$2.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-576.00K |
| % of Total Assets | -29.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VVT Med Inc. - Net Assets Trend (2022–2024)
This chart illustrates how VVT Med Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VVT Med Inc. (2022–2024)
The table below shows the annual net assets of VVT Med Inc. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$-6.38 Million | -19.12% |
| 2023-12-31 | CA$-5.36 Million | -51.30% |
| 2022-12-31 | CA$-3.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to VVT Med Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 323600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$14.28 Million | % |
| Total Equity | CA$-6.38 Million | 100.00% |
VVT Med Inc. Competitors by Market Cap
The table below lists competitors of VVT Med Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BMC
ST:BMC
|
$8.84 Million |
|
Minda Global Bhd
KLSE:5166
|
$8.84 Million |
|
SAIHEAT Limited
NASDAQ:SAIH
|
$8.84 Million |
|
va-Q-tec AG
PINK:VAQTF
|
$8.84 Million |
|
Shreyans Industries Limited
NSE:SHREYANIND
|
$8.84 Million |
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
$8.84 Million |
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
$8.83 Million |
|
Tong Herr Resources Bhd
KLSE:5010
|
$8.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VVT Med Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,356,000 to -6,380,000, a change of -1,024,000.
- Net loss of 1,040,000 reduced equity.
- Other factors increased equity by 16,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-1.04 Million | -16.3% |
| Other Changes | CA$16.00K | +0.25% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares VVT Med Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | CA$-0.05 | CA$0.21 | x |
| 2023-12-31 | CA$-0.08 | CA$0.21 | x |
| 2024-12-31 | CA$-0.10 | CA$0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VVT Med Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -211.38%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -3202.47% | 0.09x | 0.00x | CA$-2.24 Million |
| 2023 | 0.00% | -5356.10% | 0.05x | 0.00x | CA$-1.66 Million |
| 2024 | 0.00% | -211.38% | 0.50x | 0.00x | CA$-402.00K |
Industry Comparison
This section compares VVT Med Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,824,982
- Average return on equity (ROE) among peers: -368.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VVT Med Inc. (VVTM) | CA$-576.00K | 0.00% | N/A | $8.84 Million |
| Cheelcare Inc. (CHER) | $-1.89 Million | 0.00% | 0.00x | $11.70K |
| Evome Medical Technologies Inc. (EVMT) | $9.50 Million | -20.26% | 0.02x | $284.04K |
| Frequency Exchange Corp. (FREQ) | $334.04K | -1454.44% | 3.18x | $6.07 Million |
| Imaging Dynamics Company Ltd (IDL) | $-644.55K | 0.00% | 0.00x | $288.10K |